Tuesday, 23 April 2024
Trending

[the_ad_group id="2845"]

Investing

Co-Diagnostics names new President and C-suite executives By Investing.com

Co-Diagnostics names new President and C-suite executives By Investing.com

[the_ad id="21475"]

[ad_1]

SALT LAKE CITY – Co-Diagnostics , Inc. (NASDAQ:), a molecular diagnostics company, announced a significant reorganization of its executive team last month, with key appointments including Richard Abbott as President, David Nielsen as Chief Operations Officer, Christopher Thurston as Chief Technology Officer, and Seth Egan as Chief Commercialization Officer.

Richard Abbott, the newly appointed President, brings over two decades of leadership experience in in-vitro diagnostics to his new role. His previous position as President of Advanced Conceptions, a subsidiary of Co-Diagnostics, saw him play a pivotal role in the development of the Co-Dx PCR platform. Abbott’s expertise is expected to further the development and commercialization of the platform and its tests.

David Nielsen, the new COO, has a background in R&D technical and leadership roles, primarily at BioFire and BioFire Defense. He has been instrumental in the development of the Company’s platform since the acquisition of Idaho Molecular, where he previously served as COO.

Christopher Thurston, stepping in as CTO, has a history of developing software platforms for companies like Ernst and Young and BioMerieux. As a co-inventor of the Co-Dx PCR platform at Idaho Molecular, Thurston’s expertise is anticipated to drive technological advancements in the company’s offerings.

Seth Egan, the new CCO, has been with Co-Diagnostics from its inception, leading sales and marketing efforts, including the distribution of approximately 35 million Logix Smart® tests globally. His role is crucial in the commercialization of the Co-Dx PCR platform.

Dwight Egan, CEO of Co-Diagnostics, expressed his enthusiasm for the new appointments, highlighting the importance of their collective experience for the company’s growth and mission to democratize access to PCR diagnostics.

The Co-Dx PCR platform, including PCR Home™ and PCR Pro™, along with its mobile app and associated tests, is currently under regulatory review and not yet available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are under FDA review.

This announcement is based on a press release statement.

InvestingPro Insights

As Co-Diagnostics, Inc. (NASDAQ:CODX) restructures its leadership team to enhance its molecular diagnostics platform, the company’s financial health and market performance provide a backdrop for investors considering the stock. With a market capitalization of $35.32 million, Co-Diagnostics is navigating a challenging…

Click Here to Read the Full Original Article at All News…

[ad_2]

[the_ad id="21476"]